The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study

Lelisa Fekadu Assebe¹*, Hailemariam Lemma Reda¹, Alem Desta Wubeneh², Wondwossen Terefe Lerebo²
and Saba Maria Lambert³

Abstract

Background: Tuberculosis (TB) is a major public health problem that accounts for almost half a million human immunodeficiency virus (HIV) associated deaths. Provision of isoniazid preventive therapy (IPT) is one of the public health interventions for the prevention of TB in HIV infected individuals. However, in Ethiopia, the coverage and implementation of IPT is limited. The objective of this study is to compare the incidence rate of TB, TB-free survival time and identify factors associated with development TB among HIV-infected individuals on pre-ART follow up.

Methods: A retrospective cohort study was conducted from January, 2008 to February 31, 2012 in Jimma hospital. Kaplan-Meier survival plots were used to calculate the crude effect in both groups on TB-free survival probabilities and compared using the log rank test. A Cox proportional hazard model was used to identify predictors of TB.

Result: A total of 588 patients on pre-ART care (294 IPT and 294 non-IPT group) were followed retrospectively for a median duration of 24.1 months. The median CD⁴⁺ cell count was 422 cells/μl (IQR 344 – 589). During the follow up period, 49 individuals were diagnosed with tuberculosis, giving an overall incidence of 3.78 cases per 100 person year (PY). The incidence rate of TB was 5.06 per 100 PY in non-IPT group and 2.22 per 100 PY in IPT user group. Predictors of higher TB risk were: being on clinical WHO stage III/IV (adjusted hazard ratio (AHR = 3.05, 95% confidence interval (CI): 1.61, 5.81); non-IPT user (AHR = 2.02, 95% CI: 1.04, 3.92); having CD⁴⁺ cell count less than 350 cells/μl (AHR = 3.16, 95% CI: 1.04, 3.92) and between 350–499 cells/μl, (AHR = 2.87; 95% CI: 1.37 - 6.03) and having episode of opportunistic infection (OI) in the past (AHR = 2.41, 95% CI: 1.33-4.34).

Conclusion: IPT use was associated with fifty percent reduction in new cases of tuberculosis and probability of developing TB was higher in non-IPT group. Implementing the widespread use of IPT has the potential to reduce TB rates substantially among HIV-infected individuals in addition to other tuberculosis prevention and control effort in resource limited settings.

Keywords: Isoniazid preventive therapy, Incidence, TB, IPT Effect, Pre-ART care

* Correspondence: lelfekadu1@gmail.com

¹Ethiopian Federal Ministry of Health, Disease Prevention and Control
Directorate, Addis Ababa, Ethiopia

© 2015 Assebe et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Tuberculosis remains a major public health problem throughout the world. Globally almost one third of the world population is estimated to be latently infected with Mycobacterium tuberculosis and hence at risk of developing active TB disease [1]. The TB epidemic has been fuelled by HIV co-infection, one increasing the other’s impact.

HIV infection, through waning of the immune system, increases the susceptibility mycobacterium tuberculosis infection and progression to active disease [2]. The TB epidemic is further, aggravated by drug resistance, social inequalities, limited TB control efforts and limited access to health care services [3,4]. The risk of developing TB is between 20 to 37 times greater in HIV infected individuals when compared to immunocompetent individuals [5]. As a result, TB is the commonest infection and common cause of death among HIV-infected individuals [6].

According to the world health organization (WHO) 2013 global TB report, there were an estimated 8.6 million new TB cases and 1.3 million TB related deaths (a quarter of these deaths were associated with HIV). More than half of these estimated TB cases occurred in Asia and western pacific regions. HIV positive TB cases accounts for 1.1 million (13% of all TB cases) among patients with documented HIV test result. Majority of the co-infected cases (75%) were in Africa. Nearly 57% of HIV positive TB cases were on ART and 520,000 HIV-positive people were reported to have received TB preventive therapy. South Africa accounts for the highest proportion of IPT coverage (71%) [6]. This report also shows that Ethiopia ranks seventh amongst the world’s 22 high TB burden countries in the world and TB is the second leading cause of hospital death in the country [6,7]. In Ethiopia, 79% of HIV infected individuals were screened for active TB, of whom 15% had TB/HIV co-infection. Only 19% of the HIV positive clients without active TB were provided with IPT in 2010 [7,8]. This dual epidemic of HIV/AIDS and TB is a growing concern that challenges the Ethiopian government’s efforts towards prevention and control of both disease [7,9,10].

To reduce the burden of TB among HIV infected individuals, the country had adopted twelve key TB/HIV collaborative activities recommended by World Health Organization (WHO) [5-7,11]. Provision of ART significantly reduces TB/HIV related mortality and risk of incident TB [5,12]. However ART alone isn’t adequate enough in reducing tuberculosis risk in HIV infected individuals, hence implementation of other TB specific intervention to further reduce the risk of TB in HIV-infected individuals is required [5,12-14].

Multiple studies have demonstrated the effectiveness of IPT in adults [9,11,13,15-18]. Meta-analyses of randomized controlled trials have shown that IPT reduces the risk of TB by 33% overall and by 64% when targeted to HIV infected individuals who had a positive tuberculin skin test [13]. An earlier (1998) systematic review of four placebo controlled randomized trials, concluded that approximately one half of active tuberculosis cases were reduced with use of IPT [19]. Cohort and case control studies have shown that IPT provision for HIV-infected adults significantly reduce tuberculosis incidence independently or with coadministration of highly active antiretroviral therapy (HAART) [11,15-17,20,21]. In contrary three cohort studies conducted in Brazil, Tanzania, and Kenya showed IPT had no significant effect on the reduction of TB among HIV-infected individuals [22-24].

In spite of good evidence of IPT uses and the global recommendation as part of standard care for all HIV infected individuals after ruling out active TB, it was noted that the coverage and implementation had been slow in many countries including Ethiopia [7,9,18]. These problems were linked with concern about development of isoniazid related resistance, drug side effects, providers’ attitude on its effectiveness, failure to consistently use TB screening algorithms and shortage of drug supplies [18,25,26]. These factors may affect both the perception and attitude of the policy makers, health care providers and clients towards TB preventive therapy. Studies that have shown inconsistent results of IPT protection against TB may cause further misunderstanding. A critical review of barriers related to the health system and client related issues should be carried out in order to develop nation specific strategies that are essential to foster the implementation of IPT program. In Ethiopia the effect of IPT on the incidence of TB and the determinants associated with TB disease among HIV infected individuals (pre-ART) are not well studied. Furthermore little is known on TB free survival probability among IPT user and non-users. Therefore this study is aimed at investigating IPT effect and identifying determinants factors for TB among HIV-infected individual in Jimma University Specialized Hospital (JUSH), in southwest Ethiopia. The study was based on the hypothesis that there is no significant difference in TB incidence between IPT user and non-user among HIV-infected individuals.

Methods
Study setting and design
Jimma University Specialized Hospital (JUSH) is a government hospital, rendering its referral and specialized medical services to more than 15 million populations in south western Ethiopia. The hospital has enrolled more than 7,400 patients to HIV care and follow-up, among these 3,476 were on pre-ART care follow-up during the study period. A retrospective cohort study design was employed in this study.
Study period and population
The source population was HIV infected individuals enrolled in pre-ART care follow-up, whose age was between 15 and 64 years. The study population was a sample of the source population who was under care during the period January 2008 to February 2012. Exclusion criteria were incomplete patient records, past history of TB, active TB, or on treatment for TB.

Sample size determination
The sample size was determined using sample size determination formula for independent cohort studies using Epi-info version 7, for IPT and non-IPT group. Incidence of TB among IPT group 2.2% and among non-IPT group 7.5% were taken from previous study [27]. Taking ratio of exposed to unexposed 1:1 with 80% power and 5% type 1 error, the resulting total sample size was 588.

The total number of adult patients in pre-ART care was obtained from the pre-ART register (N = 3476) and patients were categorized according to IPT (n₁ = 420) and non-IPT group (n₂ = 2648). Sampling frame for IPT and non-IPT group was prepared by assigning sequentially unique number to each patient medical record in each groups separately; simple random sampling method was employed to select participant records from both groups using computer generated random numbers.

Variables and source of data
The main outcome variable was tuberculosis. Diagnosis of TB in HIV positive individuals in this analysis was based on the national guidelines for clinical and programmatic management of TB, TB/HIV and leprosy in Ethiopia. Smear-positive pulmonary TB was established if at least one sputum smear examination positive for Acid-fast bacilli (AFB). The algorithm for smear negative pulmonary TB diagnosis required at least three sputum specimens negative for AFB, radiologic abnormalities consistent with active tuberculosis, decision by a clinician to treat with full course of Anti-TB chemotherapy, or patient with AFB smear-negative sputum which is culture-positive for MTB. Extra pulmonary TB diagnosis was based on histological or strong clinical evidence consistent with active extra pulmonary, with the clinician’s decision to treat the patient with a full course of anti-tuberculosis treatment or one specimen from an extra pulmonary site culture or smear positive for AFB. For this analysis, both pulmonary TB and extra pulmonary TB were included [7].

The primary exposures of interest were initiation of IPT. Prior to initiating IPT in HIV-infected individuals, it is important to screen for TB. As a screening tool, the Ethiopian guidelines suggest a four symptoms based clinical algorithm that comprises of current cough, night sweats, weight loss and fever. HIV infected individuals without any of the symptoms are unlikely to have active TB and should be offered IPT. IPT is provided for a period of six months, with monthly follow-up until the treatment course is completed [7]. However tuberculin skin test (TST) isn’t a requirement for IPT initiation in the country [7]. We extracted data on these and other predictor variables from standard national pre-ART register, follow up forms and other clinical records. These register and forms are regularly filled as part of a routine paper-based patient record system. Important data related to socio-demographic characteristics (age, sex, marital status, level of education, religion, residence, employment status). clinical, laboratory and IPT information (past OI, clinical WHO stage, CD₄⁺ cells count, weight, other OI treatment initiation, Hgb, IPT and functional status, incident TB). Social condition and substance use (number of people in the household, tobacco use, alcohol use, soft drugs and hard drugs) were extracted by trained nurses.

Data processing and analysis
Completed questionnaires were coded, entered and analyzed using STATA version 11.1 software. Each variable was checked for missing and coding problem. Descriptive statistics was used to summarize the characteristics of the cohort.

TB incidence rate was calculated for IPT and non-IPT group in HIV-infected individuals. The TB free survival probability (survival analysis) was calculated in months using the time interval between dates registered on pre-ART care or IPT prophylaxis initiation to date of TB diagnosis or censoring. Subject was censored on the date of completion of the study, died, lost to follow-up, transferred out and ART initiated; whichever occurred first. For subjects lost to follow-up, transferred out and died, the date of their last follow-up visit was used as the censoring date.

Kaplan-Meier survival plots were used to calculate the crude effect of both groups on TB-free survival probabilities and compared using the log rank test. Crude hazard ratio test was used for inclusion of variables into multivariate analysis with cut off p-value ≤ 0.25. Cox proportional hazard model was used to identify factors associated with incidence of TB and a p-value ≤ 0.05 declares the significance of the variables at 95% confidence level.

The multivariate model was built using purposeful selection with backward elimination method [28]. Confounding was checked and percentage change in the regression coefficients (β) less than 20% reveals absence of confounder [28]. Interaction for the main effect model was checked and Partial likelihood ratio test has p-value > 0.05 and VIF < 10 indicating non-existence of multicollinearity among the variables in this study. A statistical and graphical test was used to assess the proportional hazard
assumptions and the result showed that none of the predictors violated the proportional hazard assumptions and there was no strong evidence of non-fit.

Ethical consideration
The research was approved by Institutional Review Board of Mekelle University, College of Health Science (MU-CHS) with reference number ERC 0228/2013. A support letter referred with BEFO/HBTFH/1-8/2234 was sought from Oromia Regional Health Bureau. Jimma University Specialized Hospital was informed about the objective of the study and written permission was obtained from the hospital administrator before starting data collection.

All the collected patient information was stored anonymous and data was kept confidential. More over personal identifiers was not included in the data collection forms.

Results
A total of 588 HIV infected individuals (294 IPT and 294 non- IPT cohort) were followed for a median duration of 22.61 (IQR 17.13-28.56) months in the IPT and 26.68 (IQR 14.66-43.66) months in the non-IPT group (Table 1). Among the IPT group, majority of the patients 180 (61.43%) were female. Similarly among the non-IPT group, females accounted for 62.59%. At the time of enrollment to pre-ART care, there were 124 (42.18%) and 133 (45.24%) patients under age of 29 years in the IPT and non-IPT groups, respectively (Table 1).

Clinical and laboratory characteristics, and follow-up outcome
Nearly half of the patients had at least one episode of opportunistic illness in the past, 145 (49.49%) of them were from IPT and 126 (42.86%) were from non-IPT group. Out of the total study participants, majority of IPT group patients were in clinical WHO stage I/II 256 (87.07%). The median CD4+ cell count was 422 cells/μl (IQR 344 – 589) for the entire cohort, 499 cells/μl (IQR 328-786) for IPT group, 444 cells/μl (IQR 357–613) for non-IPT group.

Out of 237 (40.51%) patients who had CD4+ cell count between 350–499 cells/μl, 121 (41.44%) were in IPT group and 116 (39.59%) of them were in non-IPT group (Table 2).

Comparison of TB incidence rate and TB-free survival time
There were 49 incident TB cases in this study cohort during 1297.5 PY of observation and the overall tuberculosis incidence rate was 3.78 per 100 PY of follow up (95% CI: 2.85, 4.99 cases per 100 PY). The TB incidence rate in the IPT group was 2.22 new cases of TB per 100 person-year (95% CI: 1.29, 3.82 cases per 100 PY) and 5.06 per 100 person-year (95% CI: 3.65, 7.02 cases per 100 PY) for non IPT group (Table 3). Individuals taking isoniazid preventive therapy were at lower risk of developing tuberculosis as compared to their counterpart with adjusted hazard ratio (AHR) of 2.02 (95% CI: 1.04 - 3.92) (Table 4).

The TB free survival proportion for the entire cohort over the follow up period was 0.77 and the TB-free survival probability in the IPT user group was significantly higher than the non-IPT user group throughout the study (log rank statistic = 4.20, df =1, P = 0.0403) (Figure 1). Furthermore Figure 1 shows the cumulative TB-free survival at thirty six months of follow-up was approximately 93% in IPT and 87% non-IPT user groups.

Predictors of tuberculosis incidence
HIV infected individuals who didn’t received IPT during the study period had two times higher risk of developing TB as compared to those who received IPT, after adjusting for past opportunistic illness, clinical WHO stage and CD4+ cell count (AHR = 2.02; 95% CI: 1.04-3.92). The presence of past episode of opportunistic illness were also associated with increased hazard of developing TB after controlling for IPT use, clinical WHO stage and CD4+ cell count (AHR = 2.87; 95% CI: 1.37 - 6.03) (Table 4).

Individuals with clinical WHO stage III/IV had nearly 3.1 times increased risk of developing TB as compared to patients in clinical WHO stage I/II after controlling for past opportunistic illness, IPT use and CD4+ cell count (AHR = 3.05; 95% CI: 1.61 - 5.81). Compared to those presenting with CD4+ cell count > =500 cells/μl, patients with CD4+ cell count less than 350 cells/μl had 3.2 times (AHR = 3.16; 95% CI: 1.04 - 3.92) and between 350 – 499 cells/μl had 2.9 times (AHR = 2.87; 95% CI: 1.37 - 6.03) higher hazard of developing TB after controlling for past opportunistic illness, clinical WHO stage and IPT use (Table 4).

In summary, HIV infected individuals with advanced clinical WHO stage, non-IPT use, low CD4+ cell count and history of past episode of opportunistic illness, were more likely to have higher incidence of TB (Table 4).

Discussion
The overall incidence of tuberculosis was 3.78 per 100PY in the entire follow-up period. This finding was consistent with a cohort study in Zambia that shows 3.6 per 100 PY [29]. However, this result was higher than study done in Brazil and Ethiopia with TB incidence 2.28 per 100 PY 2.6 per 100 PY, respectively [17,22]. This inconsistency might be due to smaller number of individuals receive IPT, some of the study participants were taking ART and difference in source population, as the source population of those study includes all age groups in the latter studies [17,22].
In our study the incidence of TB was higher among patients with no prophylaxis as compared to patients with IPT prophylaxis. This finding was in agreement with studies done in Namibia, Brazil and Ethiopia [9,11,16,17,21]. However, a cohort study in Thailand and clinical trial in Kenya showed, there was no difference in TB incidence whether a patient took IPT or not [24,30]. This difference might be explained by limited scope focusing only to see incidence of pulmonary type of tuberculosis cases in Thailand study [30]. Similarly, the benefit of isoniazid might be limited in the Kenya study due to high rate of transmission of new infection and

| Variables                        | Category       | pre-ART IPT group no (%) | Non-IPT group no (%) | Total       |
|----------------------------------|----------------|--------------------------|----------------------|-------------|
| **Age group (years)**            |                |                          |                      |             |
| 15-29                            | 124 (42.18%)   | 133 (45.24%)             | 257 (43.71%)         |             |
| 30-39                            | 108 (36.73%)   | 93 (31.63%)              | 201 (34.18%)         |             |
| 39+                              | 62 (21.09%)    | 68 (23.13%)              | 130 (22.11%)         |             |
| **Sex (n = 587)**                |                |                          |                      |             |
| Female                           | 180 (61.43%)   | 184 (62.59%)             | 364 (62.01%)         |             |
| Male                             | 113 (38.57%)   | 110 (37.41%)             | 223 (37.99%)         |             |
| **Residence (n = 585)**          |                |                          |                      |             |
| Urban                            | 201 (69.07%)   | 201 (68.37%)             | 402 (68.72%)         |             |
| Rural                            | 90 (30.93%)    | 93 (31.63%)              | 183 (31.28%)         |             |
| **Marital status**               |                |                          |                      |             |
| Never Married                    | 51 (17.35%)    | 54 (18.37%)              | 105 (17.86%)         |             |
| Married                          | 159 (54.08%)   | 156 (53.06%)             | 315 (53.57%)         |             |
| Separated                        | 31 (10.54%)    | 21 (7.14%)               | 52 (8.84%)           |             |
| Divorced                         | 31 (10.54%)    | 29 (9.86%)               | 60 (10.20%)          |             |
| Widowed                          | 22 (7.48%)     | 34 (11.56%)              | 56 (9.52%)           |             |
| **Level of education (n = 585)** |                |                          |                      |             |
| No education                     | 53 (18.21%)    | 86 (29.25%)              | 139 (23.76%)         |             |
| Primary                          | 123 (42.27%)   | 111 (37.76%)             | 234 (40.00%)         |             |
| Secondary                        | 86 (29.55%)    | 71 (24.15%)              | 157 (26.84%)         |             |
| Tertiary                         | 29 (9.97%)     | 26 (8.84%)               | 55 (9.40%)           |             |
| **Religion (n = 587)**           |                |                          |                      |             |
| Protestant                       | 35 (11.95%)    | 50 (17.01%)              | 85 (14.48%)          |             |
| Orthodox                         | 174 (59.39%)   | 133 (45.24%)             | 307 (52.30%)         |             |
| Muslim                           | 78 (26.62%)    | 104 (35.37%)             | 182 (31.01%)         |             |
| Catholic                         | 6 (2.05%)      | 7 (2.38%)                | 13 (2.21%)           |             |
| **Employment status (n = 585)**  |                |                          |                      |             |
| Employed                         | 116 (39.86%)   | 104 (35.37%)             | 220 (37.61%)         |             |
| Unemployed                       | 175 (60.14%)   | 190 (64.63%)             | 365 (62.39%)         |             |
| **People/household (n = 583)**   |                |                          |                      |             |
| <=2                              | 89 (30.38%)    | 92 (31.72%)              | 181 (31.05%)         |             |
| >2                               | 204 (69.62%)   | 198 (68.28%)             | 402 (68.95%)         |             |
| **Substance use**                |                |                          |                      |             |
| Tobacco                          | Yes            | 37 (12.63%)              | 57 (19.39%)          | 94 (16.01%) |
| No                               | No             | 256 (87.37%)             | 237 (80.61%)         | 493 (83.99%)|
| Alcohol                          | Yes            | 64 (21.77%)              | 74 (25.17%)          | 138 (23.47%)|
| No                               | No             | 230 (78.23%)             | 220 (74.83%)         | 450 (76.53%)|
| Soft drugs¹                      | Yes            | 92 (31.29%)              | 110 (37.41%)         | 202 (34.35%)|
| No                               | No             | 202 (68.71%)             | 184 (62.59%)         | 386 (65.65%)|
| Hard drugs²                      | Yes            | 31 (10.58%)              | 33 (11.26%)          | 64 (10.92%) |
| No                               | No             | 262 (89.42%)             | 260 (88.74%)         | 522 (90.08%)|
| **Follow up time median (IQR)**  |                |                          |                      |             |
| Over all                         | 24.08 (IQR = 15.63-36.98) month | | | |
| IPT                              | 22.61 (IQR = 17.13-28.56) month | | | |
| Non-IPT                          | 26.68 (IQR = 14.66-43.66) month | | | |

¹khat, "shisha", pills ²cocaïne, morphine, intravenous drug use.

Table 1 Demographic, socio-economic, substance use characteristics of the study participants in pre-ART follow up, JUSH, 2013, N = 588
insufficient duration of isoniazid provision for individuals with relatively advanced immune-suppression and non-adherence to therapy [24]. Our results suggest that the difference in incidence of tuberculosis might be attributed to the use of IPT that prevents progression of latent infection to active disease.

This study showed that IPT offers a long term benefit in HIV-infected individuals against tuberculosis with a higher TB free survival particularly during the first three years of follow up among IPT users. Therefore the use of IPT during pre-ART care shows higher decrease in cumulative risk of TB disease in HIV-infected patients. This finding agrees with observational study conducted in Spain [31].

Similarly, TB-free survival time was higher in IPT group than non-IPT group. This finding was supported by studies done in South Africa and Namibia that showed higher TB-free survival probability among IPT-group [15,21].

| Table 2 Clinical and laboratory characteristics, and follow-up outcome of the study participants on Pre-ART follow up, JUSH, 2013, N = 588 |
| Variables | Category                  | Pre-ART IPT group No (%) | Non-IPT group No (%) | Total |
|-----------|--------------------------|---------------------------|-----------------------|-------|
| Past opportunistic infection (n = 587) | Yes                      | 145 (49.49%)              | 126 (42.86%)          | 271 (46.17%) |
| WHO clinical stage                     | Stage I/II                | 256 (87.07%)              | 227 (77.21%)          | 483 (82.14%) |
|                                         | Stage III/IV              | 38 (12.93%)               | 67 (22.79%)           | 105 (17.86%) |
| Functional status                       | Working1                  | 270 (91.84%)              | 250 (85.03%)          | 520 (88.44%) |
|                                         | Ambulatory2               | 22 (7.48%)                | 43 (14.63%)           | 65 (11.05%) |
|                                         | Bedridden3                | 2 (0.68%)                 | 1 (0.34%)             | 3 (0.51%) |
| Ol treatment other than INH (n = 584)   | Given4                    | 143 (49.14%)              | 124 (42.32%)          | 267 (45.72%) |
| Hemoglobin level (n = 532)              | <=10 mg/dl                | 16 (5.90%)                | 19 (7.28%)            | 35 (6.58%) |
|                                         | >10 mg/dl                 | 255 (94.10%)              | 242 (92.72%)          | 497 (93.42%) |
| CD4 cells count (cells/μl) (n = 585)    | <350                      | 84 (28.77%)               | 69 (23.55%)           | 153 (26.15%) |
|                                         | 350 – 499                 | 121 (41.44%)              | 116 (39.59%)          | 237 (40.51%) |
|                                         | => 500                    | 87 (29.79%)               | 108 (36.89%)          | 195 (33.33%) |
| Weight (kg)                             | <40                       | 3 (1.02%)                 | 13 (4.42%)            | 16 (2.72%) |
|                                         | 40-49                     | 81 (27.55%)               | 87 (29.59%)           | 168 (28.57%) |
|                                         | 50-60                     | 117 (39.63%)              | 129 (43.88%)          | 246 (41.84%) |
|                                         | >60                       | 93 (31.63%)               | 65 (22.11%)           | 158 (26.87%) |
| Follow-up outcome                       | Alive                     | 181 (61.56%)              | 105 (35.71%)          | 286 (48.64%) |
|                                         | Lost to follow up         | 66 (22.45%)               | 109 (37.07%)          | 175 (29.76%) |
|                                         | Entry to ART              | 20 (6.8%)                 | 19 (6.46%)            | 39 (6.63%) |
|                                         | TB                        | 13 (4.42%)                | 36 (12.24%)           | 49 (8.83%) |
|                                         | Other5                    | 14 (4.76%)                | 25 (8.50%)            | 39 (6.63%) |
| Median CD4 cells count (cells/μl)       |                           | 415 (IQR 328–786)         | 444 (IQR 357–613)     | 422 (IQR 344–589) |

1Working: able to perform usual work in and out of the house.
2Ambulatory: able to perform activities for daily living.
3Bedridden: unable to perform activities for daily living.
4Cotrimoxazole, Fluconazole.
5Transferred out and dead.

years of follow up among IPT users. Therefore the use of IPT during pre-ART care shows higher decrease in cumulative risk of TB disease in HIV-infected patients. This finding agrees with observational study conducted in Spain [31]. Similarly, TB-free survival time was higher in IPT group than non-IPT group. This finding was supported by studies done in South Africa and Namibia that showed higher TB-free survival probability among IPT-group [15,21].

| Table 3 Incidence of tuberculosis per 100 person-year according to exposure category among HIV infected individuals on pre-ART follow up in, JUSH, 2013, N = 588 |
| Group      | No. of cases of tuberculosis | No. of PY | Incidence rate of TB per 100 PY (95% CI per 100 PY) |
|------------|-----------------------------|-----------|-----------------------------------------------------|
| IPT        | 13                           | 586.16    | 2.22 (1.29 - 3.82)                                   |
| non-IPT    | 36                           | 711.41    | 5.06 (3.65 - 7.02)                                   |
| Overall TB | 49                           | 1297.50   | 3.8 (2.85 - 4.99)                                   |
contrary, recent trial study conducted in Botswana shows that shorter median time to develop TB among individuals who took IPT for 6 month [32]. This variation might be due to higher risk of re-infection to tuberculosis and inadequate power in latter study.

Our study revealed IPT use has contributed to a higher reduction in hazard of acquiring tuberculosis than non-IPT use. This finding was consistent with pooled estimate of four trials carried out in Uganda, Haiti, USA and Kenya that showed approximately the same level of reduction of TB in adults infected with HIV [19]. It was also in agreement with other studies conducted in Namibia, Brazil and Ethiopia [16,17,21]. But a recent meta-analysis of ten trails revealed that IPT use was associated with a smaller reduction of TB among HIV infected individuals [33]. In contrary, other studies conducted in Brazil, Tanzania and Kenya showed that insignificant effect of IPT on the reduction of TB [22-24]. The smaller reduction of TB in the meta-analysis might be due to inclusion of studies from resource rich countries with low TB prevalence.

Table 4 Bivariate and multivariate cox proportional hazards model of incident TB among HIV infected individuals on pre-ART follow-up in, JUSH, 2013, N = 584

| Variables                              | Category            | Crude hazard ratio (95% CI) | Adjusted hazard ratio (95% CI) |
|----------------------------------------|---------------------|-----------------------------|--------------------------------|
| Age group (years)                      | 15-29               | 1.00                        |                                |
|                                        | 30-39               | 0.88 (0.48 1.62)            |                                |
|                                        | 39+                 | 0.38 (0.15 0.98)*           |                                |
| Sex (N = 587)                          | Female              | 1.00                        |                                |
|                                        | Male                | 0.61 (0.35 1.06)            |                                |
| Marital status                         | Never married       | 1.00                        |                                |
|                                        | Married             | 0.56 (0.28 1.12)            |                                |
|                                        | Separated           | 0.83 (0.29 2.35)            |                                |
|                                        | Divorced            | 0.72 (0.27 1.91)            |                                |
|                                        | Widowed             | 0.23 (0.05 1.02)            |                                |
| Level of education (N = 585)           | Primary             | 1.00                        |                                |
|                                        | No education        | 1.85 (0.95 3.63)            |                                |
|                                        | Secondary           | 1.38 (0.67 2.85)            |                                |
|                                        | Tertiary            | 0.63 (0.15 2.74)            |                                |
| People per household (N = 583)         | <=2                 | 1.00                        |                                |
|                                        | >2                  | 1.54 (0.76 3.09)            |                                |
| Tobacco use                            | Yes                 | 1.00                        |                                |
|                                        | No                  | 0.66 (0.35 1.25)            |                                |
| Alcohol use                            | Yes                 | 1.00                        |                                |
|                                        | No                  | 0.68 (0.37 1.23)            |                                |
| Past opportunistic infection (N = 587) | No                  | 1.00                        | 1.00                           |
|                                        | Yes                 | 2.57 (1.43 4.61)**          | 2.41 (1.33 4.34)               |
| WHO clinical stage                     | Stage I/ II         | 1.00                        | 1.00                           |
|                                        | Stage III/ IV       | 3.39 (1.90 6.02)**          | 3.05 (1.61 5.81)**             |
| Functional status                      | Working             | 1.00                        |                                |
|                                        | Ambulatory          | 1.29 (0.58 2.88)            |                                |
|                                        | Bedridden           | 5.65 (0.77 41.32)           |                                |
| IPT prophylaxis*                       | Yes                 | 1.00                        | 1.00                           |
|                                        | No                  | 1.95 (1.02 3.74)            | 2.02 (1.04 3.92)*              |
| CD4+cells count (cells/μl) (N = 585)   | > = 500             | 1.00                        | 1.00                           |
|                                        | 350 – 499           | 3.06 (1.47 6.37)**          | 2.87 (1.37 6.03)**             |
|                                        | <350                | 2.34 (1.02 5.39)*           | 3.16 (1.04 3.92)**             |

*Statistically significant at p ≤ 0.05 **statistically significant at p ≤ 0.01.

*Exchanging the reference at adjusted level of analysis results in (aHR = 0.5).

*Global test of proportional-hazards assumption for predictors fitted to Cox proportional hazard model was not significant (df = 5, ch² = 7.04, p = 0.218).
and study design difference [33]. The disagreement with Brazil, Tanzania and Kenya may be due to difference in number of individuals taking IPT; high rate of transmission of new infection and insufficient duration of the prophylaxis in subjects with relatively advanced immunosuppression were among the possible reason for absence of the IPT benefit in these studies [22-24].

This study showed that patients presenting with clinical WHO stages III and IV is associated with higher hazard of developing tuberculosis as compared to patients in clinical WHO stage I and II. The result was in agreement with study conducted in South Africa and Ethiopia [14,17,20]. This may be due to the fact that HIV weakens the immune system and lead, more opportunistic infections are likely to occur.

Our study also revealed that patients who suffered from opportunistic infection had higher hazard of developing TB as compared to those free of the infections in the past. Finding from a clinical trial in Uganda and case control study in Ethiopia agreed with our finding [11,34]. In this study, among the determinant factors, having lower CD4 count were associated with increased relative hazard for developing TB. The risk of TB shows a higher increase when CD4 cell counts fall below 350 cells/μl. This result is consistent with cohort studies that show gradual increase of the risk of TB when CD4+ cell count falls down [15,17,31].

Strength and limitation of the study
This is one of the few studies in Ethiopia that explored association of IPT provision with the development of TB in individuals under pre-ART care. This study did have some limitations that are shared with most studies. The retrospective nature of the study design limited to include other factors that may influence the risk of TB (house-hold income, housing condition).

Conclusion and recommendation
Provision of TB preventive therapy to all eligible HIV-infected individuals in high TB prevalence before they reach to severe form of HIV disease is an important approach to prevent and control tuberculosis. This study indicates that isoniazid preventive therapy confers a significant reduction in TB incidence among HIV infected individuals and adjustment for potential confounder didn’t alter the estimate of its effectiveness.

Efforts should be strengthened in implementing the widespread use of IPT among adult HIV-infected patients through integration with intensified case finding and development of operational guidelines for the implementation of IPT in HIV care and treatment settings.

HIV infected individuals with advanced immunosuppression and past episode of opportunistic infection were at higher risk of developing tuberculosis, which implies undertaking in depth TB screening and frequent follow up among these patient is critical in order to prevent and control tuberculosis. Further prospective studies might be needed to establish the optimal duration of its protective effect and the added benefit of isoniazid preventive therapy (IPT) among people receiving antiretroviral therapy should be established in the country.

Abbreviations
AFB: Acid fast bacilli; AHR: Adjusted hazard ratio; CI: Confidence interval; HAART: Highly active anti-retroviral therapy; HIV: Human immunodeficiency virus; IPT: Isoniazid preventive therapy; IQR: Interquartile range; JUSH: Jimma university specialized hospital; MU-CHS: Mekelle university college of health science; OI: Opportunistic infection; PY: Person year; HR: Hazard ratio; TB: Tuberculosis; TST: Tuberculin skin test; UNAIDS: United nations programme on HIV/AIDS; WHO: World Health Organization.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Concept development and study design: LFA, HLR. Identification of studies: LFA, HLR, ADW. Supervision of the study: HLR, ADW, WTL. Critically revised
the manuscript: LFA, HLR, ADW, WTL, SML. All authors read and approved the final draft for publication.

Authors’ information
Leilisa Fekadu Assebe: BSc, MSc; Hailemariam Lemma Reda: PhD; Alem Desta Wubeneh: BSc, MSc; Wondwossen Terefe Lerebo: PhD; Saba Maria Lambert: PhD.

Acknowledgements
We thank the nurses and other staff involved in collecting data. We also thank Oromia Regional Health Bureau and medical director of Jimma University Specialized Hospital for their cooperation during data collection. We would also like to acknowledge Mekelle University, College of Health Sciences for facilitating the study.

Author details
1Ethiopian Federal Ministry of Health, Disease Prevention and Control Directorate, Addis Ababa, Ethiopia. 2Department of Public Health, College of Health Sciences, Mekelle University, Mekelle, Ethiopia. 3Dermatology Department, All African Leprosy Tuberculosis and Rehabilitation Training Hospital, Addis Ababa, Ethiopia.

Received: 29 March 2014 Accepted: 30 March 2015
Published online: 10 April 2015

References
1. WHO. Global Tuberculosis Control Report Geneva. 2007.
2. Pawlovski A, Jansson J, Skold M, Rottenberg ME, Källenius G. Tuberculosis and HIV Co-Infection. PLoS Pathog. 2012;8(2):e1002464. doi:10.1371/journal.ppat.1002464.
3. Guimarães RM, Lobo AP, Siqueira EA, Borges TFF, Melo SCC. Tuberculosis, HIV, and poverty: temporal trends in Brazil, the Americas, and worldwide. J Bras Pneumol. 2012;38(6):511–7.
4. Christopher D, Brian G. The population dynamics and control of tuberculosis. Science. 2010;328:856–61.
5. WHO. Guidelines for intensified tuberculosis case finding and Isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva: Switzerland; 2011.
6. WHO. Global tuberculosis report 2013. Geneva 27: Switzerland. Available from: URL: http://www.who.int/tb/publications/global_report/en/ accessed Feb 06, 2013.
7. Federal Ministry of Health Ethiopia. Guideline for clinical and programmatic management of TB, leprosy and TB/HIV in Ethiopia. Fourth & Fifth ed. Addis Ababa: Ethiopia: 2008 & 2012. Available from: URL: http://www.who.int/hiv/resources/download/finish33/709 and http://www.who.int/hiv/pub/guidelines/ethiopia_tbpdf accessed Feb 06, 2013.
8. Asegid W, Almaz A, Frehywot E, Beniam F, Jelaludin A, Ashenafi H, et al. Findings of the pilot sentinel TB/HIV surveillance system in Ethiopia. Ethiopian Health and Nutrition Research Institute (EHNRI). 2010. report.
9. Armenu Wesen Denegueto AW, Dolamo BL. Tuberculosis case finding and isoniazid preventive therapy among people living with HIV: a cross-sectional facility based study. BMC Public Health. 2014;14(2).
10. World Health Organization. United Nations Children’s Fund, UNAIDS, scaling up priority HIV/AIDS interventions in the health sector Progress report, Geneva, Switzerland 2009.
11. Klebret KT, Yalew AW, Belaineh BS, Ares MM. Determinant Factors Associated with Occurrence of Tuberculosis among Adult People Living with HIV after Antiretroviral Treatment Initiation in Addis Ababa, Ethiopia. A Case Control Study. PLoS One. 2013;8(5):e64488. doi:10.1371/journal.pone.0064488.
12. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119–29.
13. Akolo C, Adetile J, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV-infected persons. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD000171. doi:10.1002/14651858.CD000171.pub3.
14. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19(18):2109–16.
15. Golub JE, Pronyk P, Mohapi L, Thabane N, Moshashela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631–6.
16. Pinho AM, Santos-Lopes G, Harrison L, Schechter M. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS. 2001;15:2129–35.
17. Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AMV, et al. Beneficial Effect of Isoniazid Preventive Therapy and Antiretroviral Therapy on the Incidence of Tuberculosis in People Living with HIV in Ethiopia. PLoS One. 2014(9):e104557.
18. Getahun H, Granich R, Scluler D, Gunneberg C, Blanc L, Nunn P, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 suppl S5:557–65.
19. Wilkinson D, Squire BS, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomized placebo controlled trials. BJM. 1998;317:625–9.
20. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, et al. Effect of Routine Isoniazid Preventive Therapy on Tuberculosis Incidence among HIV-infected Men in South Africa. A Novel Randomized Incremental Recruitment Study. JAMA. 2005;293(22):2719–25.
21. Teferi T, Iyaloo J, Kalibbala M, Makki M, Hango JN, Nkongolo OT, et al. Effect of primary isoniazid preventive therapy on tuberculosis incidence rate among HIV-infected adults enrolled in HIV care in northern Namibia 2012: a retrospective cohort study. AIDS 2012, Abstract no. WEPO66-Poster Exhibition. Available from URL: http://aids2012.org/Abstracts.aspx?AID=7130 accessed Feb 06, 2013.
22. Golub JE, Saraceni V, Cavalcante SC, Paecheco AG, Moutlon LH, et al. The impact of anti-retroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21(11):1441–8.
23. Kabali C, von Reyn CF, Brooks DR, Waddell R, Mtei L, Bakai M, et al. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania. Int J Tuberc Lung Dis. 2011;15(1):1515–21.
24. Hawken MP, Meme HK, Elliott LC, Chakaya JM, Morris JS, Githui WA, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS. 1997;11:1875–82.
25. Kaasa A, Jereme D, Assessa Y, Tekla A, Assessa A, Denizew A. Evaluation of collaborative TB/HIV activities in a general hospital in Addis Ababa, Ethiopia. BMC Res Notes. 2012;5:67.
26. Braun M, Wiesner P. Tuberculosis Prevention Practices and Perspectives in Physicians in Dekalb County, Public Health Rep. 1994;109(2):259–65.
27. Pape JW, Jean SS, Ho JL. Effect of isoniazid prophylaxis on the incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342:268–72.
28. Horsmer DW, Lemeshow S. Applied Survival Analysis. New York: John Wiley and Sons, Inc.; 1999.
29. Quigley MA, Mwangia A, Hosp M, Lise F,uchs D, Porter T. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV infected Zambian adults. AIDS. 2001;15:2125–22.
30. Khwanchareonporn T, Apisarnthanarak Manosuthi W, Sunkapunapong S, Mundy L. Isoniazid Preventive Therapy and Incidence of Pulmonary Tuberculosis among HIV-infected Patients on Antiretroviral Therapy: A 4-year study. Int J Tuberc Lung Dis. 2012;16(3):336–41.
31. Casado J, Moreno S, Fortu J, Antela A, Quereda C, Navas E, et al. Risk Factors for Development of Tuberculosis after Isoniazid Chemoprophylaxis in Human Immunodeficiency Virus–Infected Patients. Clin Infect Dis. 2002;34:386–9.
32. Samandari T, Agizew TB, Nyirenda S, Teda Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomized, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588–98.
33. Chunchy Gur, Scano F, Grant A, Chaisson R. Tuberculosis Preventive Therapy in the Era of HIV Infection: Overview and Research Priorities. J Infect Dis. 2007;196:552–62.
34. Whalen CC, Johnson J, Okwera A, Horn D, Huebner R, Mugyenyi P. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337:801–8.